LOTUSEYE112.50

Lotus Eye Hospital and Institute Limited

· Pharma & Health
₹ CrorePeersGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMEDDRAGARWQKMCSHILKOVAIMcap ₹234 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Inventory Days (DIO)138.85169.71164.22
Receivable Days (DSO)9.529.748.21
Payable Days (DPO)149.45149.03139.13
Cash Conversion Cycle (days)-1.0830.4233.30
Working Capital Turnover6.1911.9626.45
Asset Turnover0.720.710.65
Cash Conversion (CFO/Net Income)1.956.6939.03
CFO/EBITDA0.871.440.93
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.